More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.07B
EPS
1.87
P/E ratio
48.8
Price to sales
12.95
Dividend yield
0.959%
Beta
0.902793
Previous close
$84.84
Today's open
$84.84
Day's range
$83.21 - $85.34
52 week range
$76.35 - $107.90
show more
CEO
Roger Susi
Employees
166
Headquarters
Orlando, FL
Exchange
NASDAQ Global Market
Shares outstanding
12788153
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
What iRadimed (IRMD) Said on Its Q3 Earnings Call
iRadimed NASDAQ: IRMD reported record third-quarter revenue as shipments of its newly launched 3870 MR IV pump accelerated, while the company said it is moderating its production ramp to protect product quality.
MarketBeat • Oct 30, 2026

IRADIMED CORPORATION (IRMD) Q3 2026 Earnings Call Transcript
IRADIMED CORPORATION (IRMD) Q3 2026 Earnings Call Transcript
Seeking Alpha • Oct 30, 2026

IRADIMED CORPORATION Reports Third Quarter 2026 Financial Results
Reports revenue of $24.2 million for the third quarter of 2026, which increased by $3.0 million, or 14% compared to the same period in 2025 and increased by $3.7 million or 18% compared to the second quarter of 2026. Reports GAAP diluted EPS of $0.51 and non-GAAP diluted EPS of $0.55 for the third quarter of 2026 compared to GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.47 for the second quarter of 2026.
GlobeNewsWire • Oct 30, 2026

Riverwater Small Cap Strategy Q3 2026 Portfolio Update
During the third quarter of 2026, the Small Cap strategy slightly underperformed its benchmark, the Russell 2000 Index, in a period in which small cap stocks broadly declined. Top contributors include AtriCure and Red Violet; top detractors include Kodiak Gas Services and PDF Solutions. We initiated a position in IRadimed at the start of the quarter, replacing Talkspace after it was acquired.
Seeking Alpha • Oct 28, 2026

IRADIMED CORPORATION to Hold Third Quarter 2026 Financial Results Conference Call on October 30, 2026
ORLANDO, Fla., Oct. 23, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 third quarter financial results before the market opens on Friday, October 30, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
GlobeNewsWire • Oct 23, 2026

IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference
ORLANDO, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it will participate in the 5th Annual ROTH Healthcare Opportunities Conference.
GlobeNewsWire • Sep 23, 2026

Conestoga Micro Cap Composite Q2 2026 Leaders, Laggards, Buys And Sells
Revenue increased 19% year-over-year, reinforcing confidence that TWST's technology leadership and expanding product portfolio continue to drive market share gains. We continue to believe AORT's expanding aortic portfolio and product pipeline provide meaningful long-term growth opportunities. We remain encouraged by PLMR's disciplined underwriting approach, diversified specialty portfolio, and ability to historically deploy capital into attractive growth opportunities.
Seeking Alpha • Aug 5, 2026

iRadimed Q2 Earnings Call Highlights
iRadimed NASDAQ: IRMD reported second-quarter 2026 revenue of $20.5 million, up 0.5% from a year earlier, as the company began general-release production of its new 3870 MRI IV pump system and worked through the costs associated with an initial manufacturing ramp.
MarketBeat • Jul 31, 2026

IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcript
IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcript
Seeking Alpha • Jul 31, 2026

IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results
Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $20.5 million for the second quarter of 2026, which increased by $0.1 million, or 0.5% compared to the same period in 2025. Reports GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.46 for the second quarter of 2026.
GlobeNewsWire • Jul 31, 2026

¹ Disclosures

Open an M1 investment account to buy and sell iRadimed Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.